AgomAb Therapeutics NV Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is filed by AgomAb Therapeutics NV, a foreign private issuer, for the month of September 2026. The report, dated September 11, 2026, serves to disclose a corporate governance update rather than financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report contains no financial statements or quantitative performance data.
Material Changes
The material change disclosed in this filing is the appointment of two new members to the Company's Board of Directors:
- Marino Garcia
- Dr. Naimish Patel
These appointments were announced via a press release dated September 11, 2026, which is included as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, contingencies, or unusual items. The information in the accompanying press release is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the professional backgrounds and qualifications of the newly appointed directors, Marino Garcia and Dr. Naimish Patel.
- Review the full text of the press release (Exhibit 99.1) for any additional context regarding the board expansion.
- Confirm the effective date of the appointments and any changes to board committee assignments.